Barbara Klencke - 01 Jul 2022 Form 4 Insider Report for Sierra Oncology, Inc.

Role
Chief Medical Officer
Signature
/s/ Mary Christina Thomson, Attorney-In-Fact for Barbara Klencke
Issuer symbol
N/A
Transactions as of
01 Jul 2022
Net transactions value
-$825,000
Form type
4
Filing time
01 Jul 2022, 16:43:55 UTC
Previous filing
17 Jun 2022
Next filing
24 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock Disposed to Issuer $550,000 -10,000 -100% $55.00 0 01 Jul 2022 Direct
transaction SRRA Common Stock Disposed to Issuer $275,000 -5,000 -100% $55.00 0 01 Jul 2022 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (right to buy Disposed to Issuer $0 -11,744 -100% $0.000000* 0 01 Jul 2022 Common Stock 11,744 $268.20 Direct F1, F2
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -2,061 -100% $0.000000* 0 01 Jul 2022 Common Stock 2,061 $263.20 Direct F2, F3
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -11,399 -100% $0.000000* 0 01 Jul 2022 Common Stock 11,399 $72.80 Direct F2, F4
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -1,749 -100% $0.000000* 0 01 Jul 2022 Common Stock 1,749 $58.00 Direct F2, F5
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -4,508 -100% $0.000000* 0 01 Jul 2022 Common Stock 4,508 $94.40 Direct F2, F6
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -4,999 -100% $0.000000* 0 01 Jul 2022 Common Stock 4,999 $78.40 Direct F2, F7
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -167,091 -100% $0.000000* 0 01 Jul 2022 Common Stock 167,091 $13.31 Direct F8, F9
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -49,000 -100% $0.000000* 0 01 Jul 2022 Common Stock 49,000 $12.15 Direct F9, F10
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -30,000 -100% $0.000000* 0 01 Jul 2022 Common Stock 30,000 $16.73 Direct F9, F11
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -50,000 -100% $0.000000* 0 01 Jul 2022 Common Stock 50,000 $31.54 Direct F9, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Barbara Klencke is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option fully vested on June 11, 2019.
F2 Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
F3 The option fully vested on January 1, 2020.
F4 The option fully vested on September 30, 2019.
F5 The option fully vested on January 1, 2021.
F6 The option fully vested on January 1, 2022.
F7 The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
F8 The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F9 Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F10 On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
F11 The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
F12 The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.